Contents
Bydureon Bcise
Bydureon Bcise is an injectable prescription medicine that improves blood sugar levels in adults with type 2 diabetes mellitus when used with diet and exercise.
- Bydureon Bcise is not the recommended first choice for treating diabetes.
- Bydureon Bcise is not for people with type 1 diabetes.
- Bydureon Bcise and Bydureon are long-acting forms of the medicine in Byetta (exenatide) and should not be used together.
- The use of Bydureon Bcise in people with a history of pancreatitis is not known.
- Bydureon Bcise safety and effectiveness in children is not known.
Side Effects of Bydureon Bcise
RISK OF THYROID C-CELL TUMORS
- Exenatide extended-release increases thyroid C-cell tumors in rats, but its relevance to humans is unknown.
- Bydureon Bcise is contraindicated in patients with a personal or family history of thyroid tumors.
Bydureon Bcise may cause serious side effects including:
- inflammation of the pancreas (pancreatitis). Stop using Bydureon Bcise and seek medical attention if you have severe abdominal pain that does not go away.
- low blood sugar (hypoglycemia). Your risk for low blood sugar may increase when using Bydureon Bcise with other medicines that lower blood sugar.
The most common side effects of Bydureon Bcise include a bump at the injection site and nausea.
Nausea is most common when starting Bydureon Bcise but usually improves over time.
Report any bothersome or persistent side effects to your healthcare provider.
These are not all the possible side effects of Bydureon Bcise.
Contact your doctor for medical advice about side effects. Report side effects to the FDA at 1-800-FDA-1088.
Dosage for Bydureon Bcise
Recommended Dosing
- The recommended dose of Bydureon Bcise is 2 mg subcutaneously once every 7 days.
- The day of administration can be changed as needed, as long as the last dose was given 3 or more days before the new day.
Missed Dose
- If a dose is missed but the next dose is due at least 3 days later, administer the missed dose and resume the regular schedule.
- If the next dose is due in 1 or 2 days, skip the missed dose.
Administration Instructions
- Bydureon Bcise is for self-administration. Train patients on mixing and injection technique.
- Remove the autoinjector from the refrigerator 15 minutes before mixing to reach room temperature.
- Mix by shaking vigorously for at least 15 seconds. Bydureon Bcise should be opaque and evenly mixed.
- Visually inspect for particulate matter or discoloration before administration. Do not use if foreign matter or discoloration is present.
- Administer Bydureon Bcise as a subcutaneous injection in the abdomen, thigh, or upper arm. Use a different injection site each week.
- Do not administer Bydureon Bcise intravenously or intramuscularly.
Initializing Bydureon Bcise Therapy
Prior treatment with an immediate- or extended-release exenatide product is not required before initiating Bydureon Bcise therapy. Discontinue previous exenatide product before starting Bydureon Bcise.
Patients switching from immediate-release exenatide may experience temporary elevations in blood glucose levels for about 2 to 4 weeks.
Patients switching from another extended-release exenatide product may continue with the regular schedule.
QUESTION
What drugs interact with Bydureon Bcise?
Table 3: Clinically Relevant Interactions Affecting Drugs Co-Administered with Bydureon Bcise and Other Exenatide-Containing Products
| Orally Administered Drugs (e.g., acetaminophen) | |
| Clinical Impact | Bydureon Bcise may reduce the rate of absorption of orally administered drugs. |
| Intervention | Use caution when administering oral medications with Bydureon Bcise. |
| Warfarin | |
| Clinical Impact | Bydureon Bcise has not been studied with warfarin. Use caution when using warfarin with Bydureon Bcise. |
| Intervention | Frequent monitoring of INR is recommended for patients taking warfarin with Bydureon Bcise. |
| Concomitant Use of Insulin Secretagogues or Insulin | |
| Clinical Impact | The risk of hypoglycemia is increased when exenatide is used with insulin secretagogues or insulin. |
| Intervention | A lower dose of the secretagogue or insulin may be required to reduce the risk of hypoglycemia. |
Pregnancy and Breastfeeding
- Limited data is available on the use of exenatide in pregnant women.
- Poorly controlled diabetes during pregnancy poses risks to both mother and fetus.
- The effects of exenatide on breastfeeding and the breastfed infant are unknown.
- Exenatide was found in the milk of lactating mice, but the relevance to humans is unclear.
Summary
Bydureon Bcise is an injectable prescription medicine that improves blood sugar levels in adults with type 2 diabetes mellitus when used with diet and exercise. Side effects include pancreatitis, hypoglycemia, kidney problems, stomach problems, low blood platelet count, allergic reactions, and others.
